J.L. Babitt, M.F. Eisenga, V.H. Haase, A.V. Kshirsagar, A. Levin, F. Locatelli et al., Controversies in optimal anemia management: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference. Kidney Int. 99, 1280-95 (2021). https://doi.org/10.1016/j.kint.2021.03.020

J.W. Bazeley, J.B. Wish, Recent and emerging therapies for iron deficiency in anemia of CKD: A review. Am. J. Kidney Dis. 79, 868–876 (2022). https://doi.org/10.1053/j.ajkd.2021.09.017

Article  PubMed  Google Scholar 

F. Locatelli, Del L. Vecchio, The search for the perfect agent for anemia management in chronic kidney disease. J. Am. Soc. Nephrol. 33, 662–664 (2022). https://doi.org/10.1681/ASN.2022020173

Article  PubMed  PubMed Central  Google Scholar 

N. Chen, C. Hao, B.C. Liu, H. Lin, C. Wang, C. Xing et al., Roxadustat treatment for anemia in patients undergoing Long-Term Dialysis. N Engl. J. Med. 381, 1011–1022 (2019). https://doi.org/10.1056/NEJMoa1901713

Article  PubMed  Google Scholar 

T. Akizawa, M. Iwasaki, Y. Yamaguchi, Y. Majikawa, M. Reusch, Phase, 3, Randomized, Double-Blind, Active-Comparator (Darbepoetin Alfa) Study of Oral Roxadustat in CKD Patients with Anemia on Hemodialysis in Japan. J Am Soc Nephrol. 31, 1628-39 (2020). https://doi.org/10.1681/ASN.2019060623

A.K. Yadav, V. Kumar, V. Kumar, D. Banerjee, K.L. Gupta, V. Jha, The effect of vitamin D supplementation on bone metabolic markers in chronic kidney disease. J. Bone Min. Res. 33, 404–409 (2018)

Article  Google Scholar 

S. Fukuma, N. Kurita, M. Fukagawa, T. Akizawa, S. Fukuhara, Impact of Cinacalcet introduction on MBD management: the MBD-5D study in Japan. Kidney Int. Suppl. 3, 436–441 (2013)

Article  Google Scholar 

Q. Zhao, X. Shen, W. Zhang, G. Zhu, J. Qi, L. Deng, Mice with increased angiogenesis and osteogenesis due to conditional activation of HIF pathway in osteoblasts are protected from ovariectomy induced bone loss. Bone. 50, 763–770 (2012)

Article  PubMed  Google Scholar 

L. Yi, Y. Ju, Y. He, X. Yin, Y. Xu, T. Weng, Intraperitoneal injection of Desferal® alleviated the age-related bone loss and senescence of bone marrow stromal cells in rats. Stem Cell. Res. Ther. 12, 45 (2021)

Article  PubMed  PubMed Central  Google Scholar 

C.S. Devignes, Y. Aslan, A. Brenot, A. Devillers, K. Schepers, S. Fabre et al., HIF signaling in osteoblast-lineage cells promotes systemic breast cancer growth and metastasis in mice. Proc. Natl. Acad. Sci. U S A . 115, E992-e1001 (2018)

J. Liu, Q. Xiao, J. Xiao, C. Niu, Y. Li, X. Zhang et al., Wnt/β-catenin signalling: function, biological mechanisms, and therapeutic opportunities. Signal. Transduct. Target. Ther. 7, 3 (2022). https://doi.org/10.1038/s41392-021-00762-6

Article  PubMed  PubMed Central  Google Scholar 

L. Li, A. Li, L. Gan, L. Zuo, Roxadustat improves renal osteodystrophy by dual regulation of bone remodeling. Endocrine. 79, 180–189 (2023)

Article  PubMed  Google Scholar 

G. Wheater, M. Elshahaly, S.P. Tuck, H.K. Datta, van J.M. Laar, The clinical utility of bone marker measurements in osteoporosis. J. Transl Med. 11, 201 (2013)

Article  PubMed  PubMed Central  Google Scholar 

J.P. Brown, C. Albert, B.A. Nassar, J.D. Adachi, D. Cole, K.S. Davison et al., Bone turnover markers in the management of postmenopausal osteoporosis. Clin. Biochem. 42, 929–942 (2009)

Article  PubMed  Google Scholar 

M.B. Greenblatt, J.N. Tsai, M.N. Wein, Bone turnover markers in the diagnosis and monitoring of metabolic bone disease. Clin. Chem. 63, 464–474 (2017)

Article  PubMed  Google Scholar 

E. Lederer, Regulation of serum phosphate. J. Physiol. 592, 3985–3995 (2014)

Article  PubMed  PubMed Central  Google Scholar 

S. Yoshida, T. Saito, K. Shibagaki, K. Hirao, T. Yuza, N. Tomosugi et al., Changes of biomarkers for erythropoiesis, iron metabolism, and FGF23 by supplementation with Roxadustat in patients on Hemodialysis. Sci. Rep. 13, 3181 (2023)

Article  PubMed  PubMed Central  Google Scholar 

J. Silver, T. Naveh-Many, FGF23 and the parathyroid. Adv Exp Med Biol. 728, 92 – 9 (2012)

M. Abdalbary, M. Sobh, S. Elnagar, M.A. Elhadedy, N. Elshabrawy, M. Abdelsalam et al., Management of osteoporosis in patients with chronic kidney disease. Osteoporos. Int. 33, 2259–2274 (2022)

Article  PubMed  Google Scholar 

A.B. Reiss, N. Miyawaki, J. Moon, L.J. Kasselman, I. Voloshyna, R. Jr. D’Avino et al., CKD, arterial calcification, atherosclerosis and bone health: Inter-relationships and controversies. Atherosclerosis. 278, 49–59 (2018)

Article  PubMed  Google Scholar 

H. Sugiura, T. Yoshida, M. Mitobe, S. Shiohira, K. Nitta, K. Tsuchiya, Recombinant human erythropoietin mitigates reductions in renal Klotho expression. Am. J. Nephrol. 32, 137–144 (2010)

Article  PubMed  Google Scholar 

M.L. Noonan, P. Ni, R. Agoro, S.A. Sacks, E.A. Swallow, J.A. Wheeler et al., The HIF-PHI BAY 85-3934 (Molidustat) improves anemia and is associated with reduced levels of Circulating FGF23 in a CKD mouse model. J. Bone Min. Res. 36, 1117–1130 (2021)

Article  Google Scholar 

P. Buendía, J. Carracedo, S. Soriano, J.A. Madueño, A. Ortiz, A. Martín-Malo et al., Klotho prevents NFκB translocation and protects endothelial cell from senescence induced by uremia. J. Gerontol. Biol. Sci. Med. Sci. 70, 1198–1209 (2015)

Article  Google Scholar 

H.D. Kiers, G.J. Scheffer, van der J.G. Hoeven, H.K. Eltzschig, P. Pickkers, M. Kox, Immunologic consequences of hypoxia during critical illness. Anesthesiology. 125, 237–249 (2016)

Article  PubMed  Google Scholar 

T. Yoshida, T. Okumura, Y. Matsuo, T. Okuyama, T. Michiura, M. Kaibori et al., Activation of transcription factor HIF inhibits IL-1β-induced NO production in primary cultured rat hepatocytes. Nitric Oxide. 124, 1–14 (2022)

Article  PubMed  Google Scholar 

A. Robinson, S. Keely, J. Karhausen, M.E. Gerich, G.T. Furuta, S.P. Colgan, Mucosal protection by hypoxia-inducible factor Prolyl hydroxylase Inhibition. Gastroenterology. 134, 145–155 (2008)

Article  PubMed  Google Scholar 

Y. Yang, X. Yu, Y. Zhang, G. Ding, C. Zhu, S. Huang et al., Hypoxia-inducible factor Prolyl hydroxylase inhibitor Roxadustat (FG-4592) protects against cisplatin-induced acute kidney injury. Clin. Sci. (Lond). 132, 825–838 (2018)

Article  PubMed  Google Scholar 

T. Iantomasi, C. Romagnoli, G. Palmini, S. Donati, I. Falsetti, F. Miglietta et al., Oxidative stress and inflammation in osteoporosis: molecular mechanisms involved and the relationship with MicroRNAs. Int. J. Mol. Sci. 24, 3772 (2015)

Article  Google Scholar 

S. Hwang, A.D. Nguyen, Y. Jo, L.J. Engelking, J. Brugarolas, R.A. DeBose-Boyd, Hypoxia-inducible factor 1α activates insulin-induced gene 2 (Insig-2) transcription for degradation of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase in the liver. J. Biol. Chem. 292, 9382–9393 (2017)

Article  PubMed  PubMed Central  Google Scholar 

I. Mylonis, G. Simos, E. Paraskeva, Hypoxia-Inducible factors and the regulation of lipid metabolism. Cells. 8, 214 (2019). https://doi.org/10.3390/cells8030214

Article  PubMed  PubMed Central  Google Scholar 

T. Haraguchi, Y. Hamamoto, H. Kuwata, Y. Yamazaki, S. Nakatani, T. Hyo et al., Effect of Roxadustat on thyroid function in patients with renal anemia. J. Clin. Endocrinol. Metab. 109, e69–e75 (2023)

Article  PubMed  Google Scholar 

S. Fishbane, C.A. Pollock, M. El-Shahawy, E.T. Escudero, A. Rastogi, B.P. Van et al., Roxadustat versus Epoetin Alfa for treating anemia in patients with chronic kidney disease on dialysis: results from the randomized phase 3 ROCKIES study. J. Am. Soc. Nephrol. 33, 850–866 (2022)

Article  PubMed  PubMed Central  Google Scholar 

H. Kim, B. Oh, K.H. Park-Min, Regulation of osteoclast differentiation and activity by lipid metabolism. Cells. 10, 89 (2021). https://doi.org/10.3390/cells10010089

Article  PubMed  PubMed Central  Google Scholar